Google’s AI Co-Scientist: A Leap Forward in Biomedical Research
/0 Comments/in Artificial Intelligence/by MaxOncoACP3: A Potential Game-Changer in Prostate Cancer Theranostics —Why?
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 8/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This time, I welcome you with the Milky Way! This week, we have some exciting updates on cutting-edge treatments in clinical and preclinical trials. I hope you find them as fascinating as I do! I bet you can guess […]
ENV105 to Reverse Resistance to ADT and ARSI
/1 Comment/in Clinical Trial, Metastatic, Phase 2/by MaxUpdate: 67Cu-SAR-bisPSMA for mCRPC Has Been Fast-Tracked by FDA
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxA New Compound Looks Promising for Bone Metastasis
/0 Comments/in Not PCa related, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025
- Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors June 5, 2025
- UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC June 5, 2025